Details of the Drug Reposition

General Information of This Drug (ID: DMNLHAC)

Drug Name
Allopregnanolone   DMNLHAC
Synonyms
516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Depression DIS3XJ69 6A70-6A7Z Approved [1]
Postpartum depression DIS08UKE 6E20.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Status epilepticus seizure DISY3BIC 8A66.1Y Phase 3 [2]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Essential tremor or related tremors DISDQ3M5 8A04.1 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)